Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

NCT00641056 · Completed

Last updated 2026-05-28

This clinical trial compared the effects of once-weekly exenatide and once-daily insulin glargine on blood sugar control in adults with type 2 diabetes who were already taking metformin, with or without a sulfonylurea.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 467 people

Who can join Ages 18+ · all sexes

Timeline Started 2008-04 · est. completion 2009-11

Where 75 sites · Australia, Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Mexico, Netherlands, Puerto Rico, Russia, South Korea, Spain, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT00641056 ↗

Description as written by the study sponsor.

The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic improvements, body weight, fasting lipids, safety, and tolerability.

Treatments tested

Exenatide Once Weekly Drug

subcutaneous injection, 2.0mcg, once weekly
Insulin Glargine Drug

subcutaneous injection, variable dose, QD

Main thing measured	Change in HbA1c From Baseline to Week 26
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00641056 ↗